SCHEDULE: Rosalind Advisors Reports 7% Stake in MediWound Ltd.

Rosalind Advisors, Inc. and affiliated entities reported a 7.0% beneficial ownership stake in MediWound Ltd., including common shares and warrants.

Summary

• Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon collectively reported beneficial ownership of 912,319 common shares of MediWound Ltd.
• This aggregate amount represents 7.0% of MediWound Ltd.'s common stock outstanding, calculated based on 12,821,433 shares outstanding as of September 30, 2025.
• The reported ownership includes 749,054 common shares and 163,265 shares issuable upon the exercise of warrants.
• A blocker provision in the warrants limits exercise if it would result in beneficial ownership exceeding 9.99% of the Common Stock.
• Consequently, the actual number of shares over which the reporting persons currently have shared voting and dispositive power, after giving effect to the blocker, is 749,054 common shares, representing approximately 5.84% of the common stock.
• The securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing the control of MediWound Ltd.

Sentiment

Score: 5

Explanation: Neutral, as this is a routine disclosure of a significant ownership stake without explicit positive or negative implications for the company's operations or financial performance. The filing simply reports a change in beneficial ownership.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Increased transparency regarding significant institutional ownership and potential influence, though the filing states no intent to change or influence control.

Key Dates

Keywords

MediWound Ltd., Rosalind Advisors, Rosalind Master Fund, Steven Salamon, Gilad Aharon, Schedule 13G, Beneficial Ownership, Common Shares, Warrants, M68830104, Healthcare, Biotechnology, Investment